Hanall Biopharma Co., Ltd.

KOSE:A009420 Stock Report

Market Cap: ₩2.1t

Hanall Biopharma Future Growth

Future criteria checks 4/6

Hanall Biopharma is forecast to grow earnings and revenue by 59.3% and 18.9% per annum respectively. EPS is expected to grow by 108% per annum. Return on equity is forecast to be 11.5% in 3 years.

Key information

59.3%

Earnings growth rate

108.0%

EPS growth rate

Pharmaceuticals earnings growth31.0%
Revenue growth rate18.9%
Future return on equity11.5%
Analyst coverage

Good

Last updated30 Dec 2024

Recent future growth updates

Recent updates

Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Dec 09
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26
Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22
Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12
Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25
What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14
Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21
Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Earnings and Revenue Growth Forecasts

KOSE:A009420 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027249,35022,000N/AN/A2
12/31/2026193,81441,55022,32535,8577
12/31/2025166,20020,1837,15018,4867
12/31/2024140,9717,100-1,00016,3437
9/30/2024134,245-6,288-10,1308,834N/A
6/30/2024130,374-6,1917,36823,537N/A
3/31/2024140,1994,43911,62222,456N/A
12/31/2023134,9103,50920,44529,643N/A
9/30/2023133,3086,04920,47629,993N/A
6/30/2023129,9816,4642,73410,524N/A
3/31/2023114,812-91910,13018,084N/A
12/31/2022109,99525117,58725,264N/A
9/30/2022104,764-37610,63620,123N/A
6/30/2022100,59694910,51520,067N/A
3/31/202297,7834,2881,71912,083N/A
12/31/2021101,5948,896-8,162840N/A
9/30/202198,50016,123726,659N/A
6/30/202195,14017,778-4,1831,719N/A
3/31/202194,30420,413-5,9131,778N/A
12/31/202088,60219,765-6,460929N/A
9/30/202092,95319,714-20,156-7,468N/A
6/30/202098,83421,4571,45214,085N/A
3/31/2020106,04919,75313,73922,030N/A
12/31/2019108,45219,17412,21520,491N/A
9/30/2019105,55010,27922,57624,374N/A
6/30/2019101,5317,37310,17411,694N/A
3/31/201994,2525,8823,1305,117N/A
12/31/201891,8393,300-4,913-2,994N/A
9/30/201888,5519,00026,22628,359N/A
6/30/201889,1319,149N/A28,894N/A
3/31/201887,2046,945N/A33,291N/A
12/31/201784,2315,813N/A42,139N/A
9/30/201785,4173,586N/A7,912N/A
6/30/201781,809562N/A-325N/A
3/31/201781,8071,355N/A2,825N/A
12/31/201682,8822,026N/A3,950N/A
9/30/201682,223-3,478N/A6,046N/A
6/30/201679,584-5,817N/A6,546N/A
3/31/201679,447-7,142N/A2,205N/A
12/31/201580,023-7,077N/A-454N/A
9/30/201579,818-16,050N/A1,128N/A
6/30/201581,892-13,143N/A280N/A
3/31/201581,657-12,865N/A-1,115N/A
12/31/201480,880-12,658N/A-3,518N/A
9/30/201478,763-11,694N/A-6,993N/A
6/30/201477,511-17,134N/A-5,677N/A
3/31/201476,276-18,966N/A-8,556N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A009420 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: A009420 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A009420 is expected to become profitable in the next 3 years.

Revenue vs Market: A009420's revenue (18.9% per year) is forecast to grow faster than the KR market (9.2% per year).

High Growth Revenue: A009420's revenue (18.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A009420's Return on Equity is forecast to be low in 3 years time (11.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 09:07
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanall Biopharma Co., Ltd. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ka-hye HongDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.
null nullDBS Bank Ltd